Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin

ORENCIA Safety Surveillance in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis (JIA)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03466814

Enrollment

Registered

2018-03-15

Start date

2018-04-06

Completion date

2021-07-21

Last updated

2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Undifferentiated Arthritis

Brief summary

Observational study of abatacept in the treatment of JIA in Japan.

Interventions

OTHERNon-Interventional

Non-Interventional

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All JIA participants who initiate treatment with Orencia in accordance with the prescribing information

Exclusion criteria

* Participants receiving Orencia for an off-label indication Other protocol defined inclusion/

Design outcomes

Primary

Measure	Time frame
Number of adverse events	1 year

Secondary

Measure	Time frame
Safety measured by number of participants who receive at least 1 dose of Orencia	1 year
Efficacy measured by number of participants who receive at least 1 dose of Orencia	1 Year

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026